Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Deborah Wild: Thrilled to See GeneVentiv Selected for The NIH NHLBI Catalyze Program
Deborah Wild/LinkedIn
Oct 11, 2025, 08:48

Deborah Wild: Thrilled to See GeneVentiv Selected for The NIH NHLBI Catalyze Program

Deborah Wild, CEO, Executive Board Member, and Leadership Coach, reposted from Damon Race on LinkedIn:

”Thrilled to see GeneVentiv selected for the NIH NHLBI Catalyze Program — a strong endorsement of both the science and our team. The company’s approach to treating all hemophilia A patients with a single gene therapy holds tremendous promise.
As many of you may know, the treatment of hemophilia is very important to me. Happy to be part of the team.”

Damon Race, President and CEO of GeneVentiv Therapeutics, shared on LinkedIn:

”Proud moment for GeneVentiv Therapeutics!

Our team has been selected into the NIH NHLBI Catalyze Program, which will fund the GLP toxicology study required for our IND submission of GENV-HEM — our one-time gene therapy designed to treat all hemophilia A patients, including those with inhibitors.

This highly competitive NIH program is one of the strongest scientific and regulatory signals of confidence a pre-IND company can receive — reflecting both the strength of our data and the rigor of our development plan. By funding the most capital-intensive portion of IND-enabling work, Catalyze support increases capital efficiency, allowing investor funds to focus on valuation-driving activities — including IND preparation, regulatory engagement, and readiness for our Phase I/II clinical trial.

Execution of the GLP toxicology study will follow dose determination from our upcoming canine efficacy and safety study, scheduled to begin in January 2026, with initial data expected in late Q1 2026. Together with our ongoing NHLBI SBIR award, which supports assay development and canine studies, the Catalyze award provides broad, non-dilutive support across efficacy, safety, and regulatory preparation — a rare position for a preclinical gene therapy company.

Grateful for the continued partnership of our scientific, regulatory, and NIH collaborators as we move GENV-HEM toward the clinic and advance our gene-editing program for Pompe disease.

Read the press release here.”

Stay updated with Hemostasis Today.

Bleeding Disorder Damon Race Deborah Wild Gene therapy GeneVentiv Health Hematology Hemophilia Hemostasis Today Inhibitor Medicine NIH NIH NHLBI Catalyze Program
NewsFeed